Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” (Annals of Oncology (2013) 24(S6) (vi24–vi32), (S0923753419315613), (10.1093/annonc/mdt333))

Ann Oncol 2013; 24: vi24–vi32 (doi:10.1093/annonc/mdt333) Under the section “Adjuvant chemotherapy for early-stage disease” Long-term follow-up of the ICON 1 trial confirms the benefit of adjuvant chemotherapy, particularly in those patients at higher risk of recurrence (stage 1B/C grade 2/3, any grade 3 or clear-cell histology) [34]. Therefore, adjuvant chemotherapy should be offered not only to suboptimally staged patients but also to those optimally staged at higher risk of recurrence [I, A]. Is replaced with: Long-term follow-up of the ICON 1 trial confirms the benefit of adjuvant chemotherapy, particularly in those patients at higher risk of recurrence [34]. Therefore, adjuvant chemotherapy should be offered not only to suboptimally staged patients but also to stage IB grade 2/3, all stage IC, any grade 3 or clear-cell histology [I, A].